CI
KROS icon

Clal Insurance’s Keros Therapeutics KROS Stock Holding History

Clal Insurance’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-299,000
Closed -$12M – 147
2023
Q2 		$12M Hold
299,000
– – 0.14% 80
2023
Q1 		$12.8M Hold
299,000
– – 0.19% 71
2022
Q4 		$14.4M Hold
299,000
– – 0.22% 79
2022
Q3 		$11.2M Hold
299,000
– – 0.15% 86
2022
Q2 		$8.26M Sell
299,000
-21,000
-7% -$921K 0.11% 97
2022
Q1 		$17.4M Hold
320,000
– – 0.18% 86
2021
Q4 		$18.7M Buy
320,000
+8,865
+3% +$442K 0.2% 88
2021
Q3 		$12.3M Sell
311,135
-8,865
-3% -$315K 0.14% 108
2021
Q2 		$13.6M Hold
320,000
– – 0.16% 103
2021
Q1 		$19.7M Hold
320,000
– – 0.23% 97
2020
Q4 		$21.1M Buy
+320,000
New +$20.2M 0.29% 84

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Clal Insurance's KROS Position: Q3 2023 in Review

Clal Insurance sold out of Keros Therapeutics (KROS) in Q3 2023, closing a stake of 299,000 shares — an estimated $12M sold.

Clal Insurance first reported a position in KROS in Q4 2020 and held it in 11 quarters. The position peaked at $21.1M in Q4 2020. 107 funds tracked by Wall St. Rank hold KROS as of Q3 2023.

  • Clal Insurance reported no remaining Keros Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Clal Insurance sold 299,000 Keros Therapeutics shares in Q3 2023, an estimated $12M.
  • Clal Insurance first reported a position in Keros Therapeutics in Q4 2020 and held it in 11 quarters.
  • Clal Insurance's Keros Therapeutics position peaked at $21.1M in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2023.

Based on Clal Insurance's 13F filing for Q3 2023, filed 6 Nov 2023.